The role of histopathology in the diagnosis of essential thrombocythemia (ET) is controversial and there has been little attempt to quantitate inter-observer variability.
INTRODUCTION
The myeloproliferative disorders (MPDs) are clonal hematological malignancies comprising 3 main disorders: essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (MF) [1] [2] [3] . In 2005 the JAK2 V617F mutation [4] [5] [6] [7] was demonstrated in 95% of patients with PV and in just over half of those with ET and MF 4, [8] [9] [10] . Prior to this, the diagnosis of these disorders relied on a combination of clinical, laboratory and histological features using one of several different sets of diagnostic criteria. None of these was universally accepted, although the PVSG criteria 11, 12 and modifications 13 were adopted for major clinical trials such as ECLAP in PV 14 and PT-1 in ET 15 both established in the late 1990s. In 2001, the World Health Organisation (WHO) published its criteria for the diagnosis of MPDs [16] [17] [18] . This classification scheme is pathology-based and, compared to the PVSG criteria, introduced a heavy emphasis on bone marrow trephine morphology together with the concept of 'prefibrotic myelofibrosis' and 'true ET' as distinct disorders. In the last two years, testing for the JAK2 V617F mutation has been incorporated into new diagnostic criteria including a revised version of the WHO criteria 1, 19, 20 .
A body of published literature, predominantly originating from the Cologne Group [21] [22] [23] [24] [25] [26] , underpins the histological features described in the WHO classification of patients with thrombocythemia. In recent years, this group has produced a series of publications representing multiple retrospective analyses of an expanding and well characterised archive of trephine biopsy specimens from patients with chronic myeloproliferative diseases. In particular, the authors claim that approximately 40-
50% of patients with ET in fact have 'prefibrotic myelofibrosis' and that this entity
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(i) The morphological features of bone marrow trephines in patients with thrombocythemia can be reliably subdivided into two distinct patterns 22, 23 .
(ii) There is minimal development of marrow fibrosis over time in patients diagnosed with 'true ET' [22] [23] [24] 26 , contrasting with development of at least mild and sometimes severe fibrosis on long-term follow-up in patients with 'prefibrotic myelofibrosis' 24, 26 .
(iii) There is an apparent reduction in life expectancy in 'prefibrotic myelofibrosis' compared to 'true ET' 22, 24 .
However, the interpretation of published data supporting these claims is complicated by the retrospective nature of the patient cohort analyses [21] [22] [23] [24] [25] [26] , the apparently overlapping nature of the cohorts studied in different papers which draw similar conclusions [22] [23] [24] 26 , a failure to correct for known prognostic factors in survival analyses 22, 24, 26 and lack of details of the causes of death or definition of myelofibrotic transformation 22, 24, 26 . In addition, there has been no characterisation of the interobserver reliability of morphological features used to distinguish the proposed entities of 'prefibrotic myelofibrosis' and 'true ET', and it has only recently become possible to correlate histological findings with underlying molecular lesions. We have therefore addressed the role of bone marrow histology in a study of patients enrolled in three prospective studies of ET, including the PT-1 trial 15 .
METHODS

Study population
Newly diagnosed and previously treated patients, aged 18 years or over, who were judged by local clinicians to meet the Polycythemia Vera Study Group (PVSG) meaning that the median follow-up for the cohort from trial entry was 68 months. The study protocol was approved by institutional ethics committees in all centers, and written informed consent was obtained from all patients.
Only bone marrow trephines taken at diagnosis were considered. Trephine biopsies that were embedded in resin without decalcification had morphology that could not be compared directly with the majority of decalcified, wax embedded specimens and these were not included in the statistical analysis. Not all paraffin-embedded sections were of sufficient length or quality to enable all parameters to be assessed. The statistical analysis therefore included a core set of 370 trephine specimens greater than 5mm in length, for which all criteria could be assessed by all three hematopathologists.
Assessment of bone marrow trephine slides
Trephine sections were assessed by three hematopathologists, each with >10 years of consultant-level experience and a subspecialist interest in the myeloproliferative disorders. Consensus discussions were held to agree the criteria for assessment (table   1 and 
Statistical analysis
Inter-observer agreement for each of the individual morphological criteria was assessed using log-linear modelling of the second-order marginal tables from the 3 pairwise comparisons among the 3 hematopathologists, as described 27 . The model controlled for the marginal distributions of each of the pathologists, and fitted a linear-by-linear association term in order to measure the strength of inter-observer agreement. Since samples in different pairwise marginal tables are not truly independent, the jack-knife procedure was used to correct the point estimates and 95% confidence intervals of the parameters for this dependence in the data structure, as described 27 . Under fairly general assumptions, the linear-by-linear association term is implied by a latent structure model, suggesting that estimates of the strength of association across criteria are comparable even if criteria are scored on different scales.
The independent predictors of WHO classification score for each of the 3 hematopathologists were analysed by Bayesian proportional odds logistic regression.
Firstly, the hematopathologists provided subjective assessments of the importance of individual morphological features by apportioning 100 points amongst the 16 criteria ( figure 3A ). Then, to identify which combination of variables optimally predicted WHO classification score, the stochastic search variable selection method was used 28 , with prior probabilities for each variable being included derived from the subjective assessment of weights (0.05 for variables given no weight by the pathologist, and 0.3+0.03x(weight) for other variables, although the results were not sensitive to the priors used). The WHO classification score was assumed to follow a latent normallydistributed variable, and data augmentation used to estimate this underlying metric from the observed discrete response. A proportional odds probit model was estimated by constrained Gibbs sampling of the cut-points, augmented data and model parameters, as described 29 . Finally, the model with the highest posterior probability was fitted to data scaled so that all predictors had the same range, in order to allow estimation of the relative contributions of each variable to the WHO score. To apply exploratory factor analysis, we took the consensus score from the 3 hematopathologists for each of the 16 criteria on all 370 diagnostic bone marrow trephines. Where there was disagreement, the median of the scores from the 3 hematopathologists was taken. Kaiser's criterion (number of eigenvalues >1) was used to determine the number of factors to fit, and the model was estimated using the varimax rotation.
RESULTS
To establish the role of bone marrow histopathology in the diagnostic evaluation of a patient presenting with thrombocytosis, bone marrow biopsy specimens were obtained from patients enrolled in three prospective trials of ET. 370 diagnostic trephine specimens were studied independently by three experienced hematopathologists for 16 morphological criteria (table 1, figure 1 ). Each hematopathologist made an overall diagnosis from the trephine histology according to the WHO criteria.
Inter-observer agreement when assessing morphological features
Many measures of inter-observer agreement, such as Cohen's kappa score, fail to correct for differences in the pattern of scores for each observer. We therefore used log-linear modelling of pairwise inter-observer agreements 27 , a well-established method that explicitly models the strength of association among the observers after correcting for the distribution of scores in the cohort studied. The method estimates the odds that if two observers score two trephine specimens in adjacent categories, then they agree on which biopsy is in which category. An estimate of 1 implies no agreement beyond chance, and the greater the estimate is above 1, the more agreement there is among the observers.
A number of interesting patterns emerged from these inter-observer comparisons (table 1) ET' ranged from 10% to 48%, 'prefibrotic myelofibrosis' from 9% to 28%, and higher levels of fibrosis from 37% to 76%. Secondly, the strength of association for cellularity criteria was generally greater than that for megakaryocyte morphological criteria, with the exception of bare megakaryocyte nuclei. In particular, agreement on the frequency of dysplastic megakaryocytes was very poor, barely above chance, with agreement on staghorn and cloud-like megakaryocytes little better. Thirdly, agreement for both the number of megakaryocyte clusters and the size of clusters was greater than for whether clusters were tight or loose. Fourthly, inter-observer agreement on the presence or absence of new bone formation was excellent. We considered the possibility that poor inter-observer agreement reflected one discrepant observer. However pairwise comparisons were similar for all pairs (data not shown) suggesting that differences in agreement shown in table 1 were not due to an 'outlier' observer.
In summary, agreement was better for measures of general morphological patterns such as cellularity, number of clusters, and reticulin grade, and weaker for measures of individual cellular features such as megakaryocyte morphology and whether clustering is tight or loose. In addition, the hematopathologists showed poor agreement in synthesising the various parameters when assigning cases to individual diagnostic categories using WHO criteria.
Relative importance of different morphological criteria: significance of reticulin grade
The WHO monograph lists several histological features that are said to be characteristic of 'true ET', such as the presence of staghorn megakaryocytes, normal overall cellularity and loose megakaryocyte clustering. In contrast, 'prefibrotic myelofibrosis' is said to be characterised by the presence of tight megakaryocyte clusters, cloud-like, dysplastic or pyknotic megakaryocytes and abnormal cellularity.
The poor inter-observer agreement for the WHO classification that we have found could result from two potential causes, which are not mutually exclusive. The hematopathologists may not agree on the interpretation of the individual criteria themselves, as demonstrated in the previous section. In addition, they may put differing emphasis or weight on the relative importance of the various morphological criteria.
The WHO monograph provides minimal guidance as to the relative importance of the various morphological features as individual contributions to reaching a diagnosis.
We found this to be problematic since we not infrequently found examples of bone marrow histology with some of the morphological features said to reflect 'true ET'
and coexistent with changes thought to imply 'prefibrotic myelofibrosis' or even overt These results demonstrate that reticulin grade was the major factor determining WHO classification assignment by all three hematopathologists. Since inter-observer agreement was quite high for reticulin grade, this suggests that the poor inter-observer agreement for WHO diagnosis was largely driven either by differences in the interpretation of the other morphological criteria, and/or by the relative importance applied to them.
No difference in presenting blood counts or clinical outcome between 'true ET' and 'prefibrotic myelofibrosis'
One of the central claims of the WHO classification is that 'prefibrotic myelofibrosis'
and 'true ET' are biologically distinct disorders with different prognoses. Due to the poor inter-observer reliability with which these putative entities could be identified, the only means to assess the reproducibility of these claims in our cohort was to compare presenting blood counts and clinical outcomes between 'prefibrotic myelofibrosis' and 'true ET' for each hematopathologist separately.
There were no differences in hemoglobin, platelet count or white cell count at diagnosis between cases labelled as 'true ET' and 'prefibrotic myelofibrosis' for any of the hematopathologists (p>0.1 for all 3 hematopathologists and each blood count variable). Similarly, there were no differences between 'true ET' and 'prefibrotic myelofibrosis' in age, sex or rates of splenomegaly, leukoerythroblastic blood film and cytogenetic abnormalities for any of the hematopathologists (p>0.1 all variables).
There was a weak association between JAK2 positivity and 'prefibrotic myelofibrosis'
for one of the pathologists ('true ET' 38% V617F-positive; 'prefibrotic myelofibrosis' 61% V617F-positive; p=0.04), but this was not found for the other two (p=0.9 and
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From p=0.1). Given the large number of hypothesis tests performed in this section, this single significant test is likely to be due to the play of chance. Finally, we were unable to identify any distinguishing diagnostic clinical or laboratory features even when subsets of patients identified as 'prefibrotic myelofibrosis' by any two or all three hematopathologists were considered (data not shown).
In total, 143 of the 370 patients were identified by at least one of the hematopathologists as having 'prefibrotic myelofibrosis' (32 hematopathologist 1, 
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We next compared 'prefibrotic myelofibrosis' and 'true ET' for each of the individual end-point categories that comprized the composite end-point, noting that numbers of events were generally low in these individual categories. There were no differences in overall survival between patients labelled as 'true ET' and 'prefibrotic myelofibrosis' for any of the three hematopathologists and furthermore, there were no differences in rates of arterial thrombosis, rates of venous thrombosis or rates of major hemorrhage between patients labelled as 'true ET' and those labelled as 'prefibrotic myelofibrosis' (p>0.1 for all three hematopathologists on univariate and multivariate analysis on each individual end-point).
Exploratory factor analysis identifies megakaryocyte clustering, degree of fibrosis and cellularity as independent underlying processes in ET
The practice of histopathology is, to a great extent, concerned with the recognition and description of patterns of morphological features. Individual morphological features of the marrow are of little intrinsic value in isolation, but represent manifestations of underlying pathophysiological factors. In our analysis, we found many significant correlations among the individual morphological features (table 2), suggesting that many features coexist and there may be coherent patterns of histological abnormalities. Factor analysis is a multivariate statistical method that seeks to identify these unobserved pathophysiological processes by picking out patterns of correlations among the morphological features that suggest common underlying, independent processes (or factors) 30 .
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We start with the third factor, since it has the most straightforward interpretation. It is particularly weighted towards cellularity criteria, with emphasis on overall cellularity as well as the degree of hypercellularity for each of the three lineages separately. An association between JAK2 status and marrow cellularity has been demonstrated previously in patients with ET, with V617F-positive ET showing greater overall, erythroid and granulocytic cellularity than V617F-negative ET 10 . Consistent with this observation, we found a significant association between the JAK2 V617F mutation and scores for this cellularity factor (p=0.0002). In contrast, there were no significant associations between JAK2 status and the other 2 factors, discussed below (p=0.1 for the clustering factor and p=0.4 for the fibrosis factor).
Considering now the other two factors, the first is particularly weighted towards number, size and type of megakaryocyte clusters together with megakaryocyte size and cellularity, and captures an underlying process related to megakaryocyte clustering. The second independent factor appears to relate to the extent of fibrosis.
Trephine specimens with extensive reticulin fibrosis, new bone formation, frequent pyknotic or dysplastic megakaryocytes, and bare megakaryocyte nuclei would score particularly highly on this factor. These are all features the WHO monograph identifies as suggestive of a diagnosis of overt myelofibrosis.
This factor analysis suggests that three underlying processes describe many of the morphological patterns evident in the bone marrow trephine histology of patients diagnosed with ET (by PVSG criteria), namely cellularity, megakaryocyte clustering and extent of fibrosis. The cellularity factor shows significant correlation with JAK2
status, but the other two reflect unknown biological mechanisms.
DISCUSSION
ET has long been thought to represent a heterogeneous disorder, likely to contain pathogenetically distinct subgroups united by the lack of positive diagnostic markers.
In keeping with this concept, histological features of bone marrow in ET, as defined by PVSG criteria, show substantial variability. This has led to attempts to subclassify the disorder on the basis of trephine morphology [16] [17] [18] 31, 32 , neither is available in routine diagnostic practice and it is hard to see the general utility of criteria the application of which is so difficult even for experienced hematopathologists. Moreover our results were obtained as part of a focused assessment in a finite period during which a large number of MPD trephine biopsy specimens were reviewed, a situation which is likely to enhance intra-observer reproducibility. Application of the criteria is likely to be significantly more difficult for most histopathologists who see such specimens relatively infrequently.
An alternative explanation for our results, and the one we favor, is that the current WHO histological criteria are not sufficiently robust to define subtypes of ET. There was poor inter-observer agreement on what is represented by the terms 'prefibrotic myelofibrosis' and 'true ET', and there were striking differences in the emphasis each of the hematopathologists placed on different morphological criteria when arriving at a diagnosis ( figure 3 ). These results demonstrate that the published histological criteria for these proposed entities are difficult to apply in a reproducible manner. It has been suggested that patients labelled as having 'prefibrotic myelofibrosis' have a worse outcome compared to those said to have 'true ET' [21] [22] [23] [24] [25] [26] , a key argument supporting the existence of these putative entities. However, we have been unable to reproduce these findings. There were no differences in the rates of thrombosis, major hemorrhage, myelofibrotic transformation or survival between 'prefibrotic myelofibrosis' and 'true ET' as labelled by any of the hematopathologists. We cannot exclude the possibility that prolonged follow up or greater numbers of patients might reveal differences in outcome. However, if such large sample sizes are required to show statistical significance, such differences are unlikely to be clinically relevant.
Our favored interpretation is also consistent with recent molecular genetic insights.
The subgroup of ET patients who carry the JAK2 V617F mutation are biologically distinct from those lacking the mutation, both in presenting features and in clinical outcome 10, [33] [34] [35] . The JAK2 V617F negative subgroup is also heterogeneous. An activating mutation in MPL occurs in approximately 10% of this subgroup 36 but the molecular mechanisms responsible for the rest remain unclear. However, there is no evidence for any correlation between the molecular subtypes of ET and the proposed histological subtypes, 'true ET' and 'prefibrotic myelofibrosis'. In patients with ET, the JAK2 V617F mutation was associated with increased overall cellularity, increased erythropoiesis and increased granulopoiesis but there was no association between JAK2 status and reticulin grade, megakaryocyte clustering or the presence of staghorn, cloud-like, dysplastic or pyknotic megakaryocytes 10 .
The results presented here suggest that current histological criteria are not sufficient to permit routine separation of ET into biologically distinct subsets. However, It is generally accepted that there is histological heterogeneity within the group of patients labelled as ET using PVSG criteria. The molecular basis for this heterogeneity is unclear and our data cast doubt on the concept of using current histological criteria to divide ET into 'true ET' and 'prefibrotic myelofibrosis'.
However, our results are consistent with a recent molecular classification of the MPDs 1 in which it is suggested that reticulin accumulates to a variable extent in patients with ET ( figure 5 ). In this model, patients with both ET and PV gradually accumulate reticulin fibrosis as an inherent part of their disease, with the degree of fibrosis reflecting an interplay between the duration of the disease and physiological or genetic modifiers. This concept is supported by histological studies 42, 43 in patients with these disorders, and the frequent development of post-polycythemic myelofibrosis in mouse models 44, 45 . The development of fibrosis is likely to be influenced by inherited genetic modifiers (as evidenced by differences in the rates of myelofibrosis among different strains of mice expressing JAK2 V617F 45 ), environmental factors and acquired genetic 46 ET share several features 10, 33, 34 , and represent a phenotypic continuum, with homozygosity for the V617F mutation strongly favoring a polycythemic phenotype 48 .
Patients labelled as primary myelofibrosis are clinically indistinguishable from those with myelofibrotic transformation of a preceding MPD 49 . The model also predicts that the genetic lesions responsible for V617F-negative primary myelofibrosis will be found in V617F-negative ET, as has been found for MPL W515 mutations 36, 50 . 
